Download Citation
Article Source:
Cost-effectiveness of a “treat-all” strategy using Direct-Acting Antivirals (DAAs) for Japanese patients with chronic hepatitis C genotype 1 at different fibrosis stages
Suenaga R,
Suka M,
Hirao T,
Hidaka I,
Sakaida I,
et al.
(2021)
Cost-effectiveness of a “treat-all” strategy using Direct-Acting Antivirals (DAAs) for Japanese patients with chronic hepatitis C genotype 1 at different fibrosis stages.
PLOS ONE 16(4): e0248748.
https://doi.org/10.1371/journal.pone.0248748